Keywords: gilead, reports, full, data, cf, drug, trial
Gilead reports full data from CF drug trial
Article | 30 April 2007
US biopharmaceutical company Gilead Sciences says that its inhaled antibiotic, aztreonam lysine, increased the time until further inhaled or intravenous ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Is the diabetes market facing a blockbuster-free future?
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
